Noile-Immune Biotech Inc. [4893.T]
TOKYO, May 14 (Pulse News Wire) – Noile-Immune Biotech Inc. (4893.T) reported a net loss of ¥152.8 million for the quarter ending March 31, 2026, compared to a loss of ¥239.2 million in the same period last year.
Revenue was not recorded during the quarter due to ongoing research and development activities. Operating expenses reached ¥174.8 million, up from ¥174.8 million in the previous year's first quarter. The company continued its focus on developing PRIME technology-based cancer therapies, achieving the first patient dosing for NIB103 in Phase I clinical trials. Other internal pipelines such as NIB104 and NIB105 are advancing towards early clinical stages.
Additionally, the firm received ¥45 million in government grants supporting its research efforts. As of March 31, 2026, total assets stood at ¥3.844 billion, down from ¥4.011 billion at the end of the previous fiscal year. Shareholders' equity decreased to ¥3.931 billion from ¥3.931 billion, reflecting the quarterly net loss. Noile-Immune Biotech did not provide guidance for the full fiscal year, citing uncertainties surrounding future developments in its pipeline projects.
The company plans to disclose updated forecasts once more concrete data becomes available.
🟡 Confidence: Standard AI-translated content.